Literature DB >> 30256943

Long-term outcomes of advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy followed by surgery: a 20-year experience.

Ryu Kanzaki1,2, Takashi Kanou1,2, Naoko Ose1,2, Soichiro Funaki1,2, Yasushi Shintani1,2, Masato Minami1,2, Hiroshi Kida2,3, Kazuhiko Ogawa2,4, Atsushi Kumanogoh2,3, Meinoshin Okumura1,2.   

Abstract

OBJECTIVES: The results of preoperative chemotherapy or chemoradiotherapy followed by surgery for locally advanced thymoma were analysed.
METHODS: Between 1997 and 2016, 29 patients with a thymoma underwent preoperative chemotherapy or chemoradiotherapy followed by surgery. These cases were retrospectively reviewed.
RESULTS: The study population included 9 men and 20 women, with a mean age of 48.8 years (range 31-68 years). The preoperative Masaoka stage was III in 12, IVa in 13 and IVb in 4 patients, whereas histological type was B3 in 11, B2 in 9 and others in 5 patients. The mean tumour size was 8.0 ± 2.5 cm (3.4-15.0 cm). The site of infiltration shown in preoperative radiological examinations was the aorta in 6 patients, the superior vena cava in 14 patients and the pulmonary artery trunk in 3 patients, with pleural dissemination detected in 14. Three patients underwent chemoradiotherapy. Chemotherapy regimens given were cisplatin + doxorubicin + vincristine + cyclophosphamide in 9 patients, carboplatin + paclitaxel in 6 patients, cisplatin + doxorubicin + methylprednisolone in 5 patients and others in 9 patients, with partial response obtained in 11 patients and stable disease noted in 18 patients. Complete resection was achieved in 24 (83%) cases. There were no perioperative mortalities, whereas 6 (21%) patients developed postoperative complications. The 5- and 10-year overall survival rates were 100% and 87%, respectively, and 5- and 10-year disease-free survival rates were 50% and 50%, respectively.
CONCLUSIONS: Preoperative chemotherapy or chemoradiotherapy followed by surgery for locally advanced thymoma can be performed with an acceptable degree of surgical risk. Such a strategy should be proactively considered, as it can lead to favourable long-term results.
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Chemotherapy ; Surgery; Thymoma

Mesh:

Substances:

Year:  2019        PMID: 30256943     DOI: 10.1093/icvts/ivy276

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  4 in total

Review 1.  Surgical management of thymic epithelial tumors.

Authors:  Yasushi Shintani; Soichiro Funaki; Naoko Ose; Takashi Kanou; Eriko Fukui; Kenji Kimura; Masato Minami
Journal:  Surg Today       Date:  2020-07-10       Impact factor: 2.549

2.  Surgical feasibility and long-term outcome of superior vena cava replacement for advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy.

Authors:  Zhen Yu; Lei Yu; Tao Yu; Xing-Guo Yang; Bao-Xun Zhang; Xin Du
Journal:  Thorac Cancer       Date:  2021-02-10       Impact factor: 3.500

Review 3.  Surgery for recurrent thymoma during the COVID-19 pandemic: a narrative review.

Authors:  Rajdeep Bilkhu; Andrea Billè
Journal:  Mediastinum       Date:  2021-06-25

4.  Improving outcomes of surgery in advanced infiltrative thymic tumours: the benefits of multidisciplinary approach.

Authors:  Andrea Billè; Rajdeep Bilkhu; Giulia Benedetti; Gianluca Lucchese
Journal:  Tumori       Date:  2021-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.